TW200908892A - Nutritional dosage unit - Google Patents
Nutritional dosage unit Download PDFInfo
- Publication number
- TW200908892A TW200908892A TW097129487A TW97129487A TW200908892A TW 200908892 A TW200908892 A TW 200908892A TW 097129487 A TW097129487 A TW 097129487A TW 97129487 A TW97129487 A TW 97129487A TW 200908892 A TW200908892 A TW 200908892A
- Authority
- TW
- Taiwan
- Prior art keywords
- vitamin
- dosage unit
- formulated
- sustained release
- meg
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title description 9
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 34
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 33
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 33
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 33
- 210000002784 stomach Anatomy 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 31
- 229940088594 vitamin Drugs 0.000 claims description 26
- 229930003231 vitamin Natural products 0.000 claims description 26
- 239000011782 vitamin Substances 0.000 claims description 26
- 235000013343 vitamin Nutrition 0.000 claims description 25
- 238000013268 sustained release Methods 0.000 claims description 18
- 239000012730 sustained-release form Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 15
- 229930003268 Vitamin C Natural products 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 239000011720 vitamin B Substances 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 11
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 230000037406 food intake Effects 0.000 claims description 9
- 239000007937 lozenge Substances 0.000 claims description 8
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 7
- 229940045999 vitamin b 12 Drugs 0.000 claims description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 229930003571 Vitamin B5 Natural products 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- 229960002079 calcium pantothenate Drugs 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 235000009492 vitamin B5 Nutrition 0.000 claims description 4
- 239000011675 vitamin B5 Substances 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 208000008081 Intestinal Fistula Diseases 0.000 claims 1
- 229940093797 bioflavonoids Drugs 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 25
- 210000000936 intestine Anatomy 0.000 abstract description 8
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract description 5
- -1 poly(vinyl phthalate) Polymers 0.000 description 19
- 239000000203 mixture Substances 0.000 description 12
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229940029329 intrinsic factor Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960002380 dibutyl phthalate Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- DMIMWGHYIPFAIF-UHFFFAOYSA-N 5-nitro-2-piperidin-1-ylaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1N1CCCCC1 DMIMWGHYIPFAIF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- MURWRBWZIMXKGC-UHFFFAOYSA-N Phthalsaeure-butylester-octylester Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC MURWRBWZIMXKGC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229960003487 xylose Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIDOPANCAUPXNH-UHFFFAOYSA-N 1,2,3-triethylbenzene Chemical compound CCC1=CC=CC(CC)=C1CC VIDOPANCAUPXNH-UHFFFAOYSA-N 0.000 description 1
- KIVXOMLVGJGWCH-UHFFFAOYSA-N 1-o-ethyl 2-o-phenyl benzene-1,2-dicarboxylate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OC1=CC=CC=C1 KIVXOMLVGJGWCH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
- NNHZAIOFDBXPGV-UHFFFAOYSA-N bis(8-methylnonyl) benzene-1,2-dicarboxylate;phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O.CC(C)CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC(C)C NNHZAIOFDBXPGV-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
- 229960002097 dibutylsuccinate Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- VJHINFRRDQUWOJ-UHFFFAOYSA-N dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Surgical Instruments (AREA)
Description
200908892 九、發明說明: 【發明所屬之技術領域】 本文描述一種用於傳遞維生素、礦物質及益生菌以維 持人類個體健康之營養補充系統。 ^ 特疋§之,本文描述一種向人類個體傳遞維生素 之系統。 ' 【先前技術】 維生素及礦物質製劑通常作為一般營養補充劑投予❶ 微置營養為以少量或痕量存在於食物及草本植物中之元素 或化合物。其包括維生素、礦物質或其他元素及食物中發 現之物質。巨量營養由碳水化合物、脂肪及蛋白質組成, 其提供營養及卡路里。諸如鈣、鈉、鉀、氯及磷之—些元 素以相對較大量消耗,而諸如鐵、碘及鋅之許多元素以較 少量消耗。諸如維生素B12及葉酸之維生素及礦物質銅、 石西及鉻以極小量或痕量消耗。 由於人體不能合成人體必需之許多化合物,故某些維 生素、礦物質及其他營養僅可獲自兩個來源,食物及補充 4。所有營養之主要來源為食物β然而,許多人不能自其 食用之食物獲得最佳量之必需化合物及元素。因此,營養 補充成為保持良好健康狀態之公認方法。 食用益生菌補充劑亦可有益於人類健康。已認識到暫 時性或慢性消化症狀可能由受損或紊亂之腸菌族造成。食 用含有合適微生物之營養補充製劑通常足以減輕或消除由 紊亂或受損之腸菌族造成之症狀。 200908892 如本文中所使用之「益生菌」係指食物補充劑中所傳 遞之活微生物’其藉由改良宿主動物之腸内微生物平衡而 有利地影響該宿主動物。抗生素及其他相關化合物不包括 於該定義中(J. iVWr. 1995;125:14〇1_12)。對於人類而言, 乳桿菌屬(MdoMcz·/// )通常作為益生菌以純種形式或與 其他細菌之混合培養物形式提供。已使用之其他屬為雙叉 桿菌屬及鏈球菌屬(以re/?i〇c〇ccz·)。「益 菌助生質」(prebiotic)係指不可消化之食物成份,其藉由 選擇性刺激結腸中細菌之生長及/或活性而有利地影響宿 主。 ^
許多先前營養補充系統具有以下問題:其提供不完全 之營養,或必須在多個不同時間服用多劑量之營養以達成 對使用者的良好平衡且適當延時之營養傳遞。先前營養補 充系統在一些情況下將營養傳遞至消化道中儘管對於營養 吸收有效但造成使用者不適之位置中。在其他情況下,在 對於身體吸收並非最佳之位置中釋放一或多種營養。當營 養或益生菌於不利之位置中釋放時,可能產生降低之:: 活性。舉例而言,益生菌通常在暴露於胃酸下不能存活。 一,·π η 在因子」之醣蛋白,此為調配用於傳遞維生素Βΐ2之補充 劑中之特定問題一般而言,維生素Β12易於在小腸通往 已發現維生素B12吸收需要胃黏膜細胞分泌稱為 大腸之最後部》(迴腸)中吸收。然而,為了被吸收,維 生素必須與内在因子組合。通過胃之後,維生素B12附著 於内在因子上以進行轉移。維生素與内在因子之該組合隨 200908892 後會由迴腸接受器「捕捉」到。在無内在因子的情況下, 大量維生素B12可保留於腸中且於糞便中排泄。先前已認 為,為使維生素B 12吸收最大化,補充劑應經調配以於胃 中傳遞維生素B12從而使與内在因子之結合最大化且優化 内在因子/B 12複合物之吸收。然而提供維生素B12在胃中 之迅速釋放的補充劑存在著困難。 因此仍需要向身體有效傳遞有益物質之使用者友好系 統。 詳細敘述 【發明内容】 回應於上述需要,提供一種在消化道之適當位置處提 供營養之營養補充系統。 特疋s之,調配一種劑量單元以在上Gi道之胃與腸 中隨時間釋放維生素Β 12。 一種四組份口服營養補充系統可有利地在人類個體之 消化道範圍内之最佳位置處提供營養及/或益生菌之組合以 達成有效之營養利用及使用者舒適性及便利性。 該系統包括第一劑量單元’其經調配以在人類個體之 月中迅速釋放一或多種營養。該劑量單元有利地包括維生 素及礦物資或其他勝食補充成份’該等成份受益於在胃中 釋放及暴露於胃酸,或不會受該釋放或暴露之不利影響, 及/或適當地分散於胃中以達成在GI道更下端處之最佳吸 收° §亥劑量單元有利地呈壓製而成之鍵:劑(tablet)或囊片 (caplet)形式。錠劑可塗佈有含有最佳在胃中特別迅速傳遞 200908892 之一或多種營養之層。一般而言,第一劑量單元不應含有 月不能良好耐受或將由胃之酸性環境損害之物質;該等物 質應在本文所述之其他劑量單元中之一者中傳遞。 第二劑量單元經調配以含有無需在胃中釋放及暴露於 胃酸以達成有效消化及吸收之營養,且該等營養當在胃中 釋放時可能產生对受性問題(反胃(repeating)、胃不適、 二^)或生物活性損失。該劑量單元有利地用於傳遞某些 呂養’由,特別為魚油組份、其他含ω—3脂肪酸之油,且亦 可包括無需胃消化之脂溶性微量營養,諸如維生素A、D、 E及類胡蘿蔔素。該劑量單元有利地為經密封之明膠膠囊 封裝,其可通過胃隨後釋放經膠囊封裝之營養。 特別重要地,第三劑量單元經調配以含有通常極迅速 吸收且口此最佳藉由持續釋放來傳遞以保持體内隨時間升 门之/辰度的水溶性營養及其他營養。該劑量單元經設計以 便以大體線性之方式緩慢釋放維生素Β12。該劑量單元可 經調配亦釋放-或多種水溶性營養,尤其其他Β維生素及 、隹生素C忒等營養之釋放最初在上GI道之胃中,且於上 GI道之腸中繼續。 —第四劑量單元含有營養及/或其他補充成份,諸如益生 菌其又暴露於月酉曼或胃消化之不利影響而應傳遞至小腸 之下端邰刀中以達成在大腸中之完全活性。該劑量單元經 調配以保護益生微生物在劑量單元通過胃期間免受可能致 命之酸暴露之影響。有利地,其係、呈三層膠囊之形式。 該等劑量單元有利地採用各種形式之延長釋放賦形劑 200908892 或包衣以及即刻釋放賦形劑或包衣從而以不同最佳釋放速 率傳遞各種維生素及礦物質補充劑。舉例而言’可使用葉 酸微包衣以在進入胃中數分鐘内自多維生素及礦物質補充 劑釋放葉酸。凝膠擴散技術可用於最大化維生素B及維生 素C之腸内吸收歷時超過12小時。提供於延緩釋放膠囊 中之魚油使得其在上GI道之腸中迅速釋放,由此產生最 大生物可用性及最小胃不適性。而三層膠囊封裝系統使得 益生菌標靶釋放至下GI道。 【實施方式】 一般而言,一般熟習此項技術者瞭解如何調配具有各 種不同釋放分布型之劑量單元。營養補充劑量單元可採用 一或多種釋放形式,包括(但不限於)即刻釋放、延長釋 放、脈衝釋放、可變釋放、控制釋放、延時釋放、持續釋 放、延緩釋放、長效及其組合❶各種類型之釋放可使用熟 知程序及技術實現。
200908892 言之’適用於實務中之包衣材料包括(但不限於)聚合物 包衣材料、水凝膠及凝膠形成材料及親水性聚合物。較佳 t合物包衣材料為鄰苯二甲酸乙酸纖維素,三順丁稀二酸 乙酸纖維素,鄰苯二甲酸羥丙基甲基纖維素,聚鄰苯二曱 酸乙酸乙烯酯,胺基甲基丙烯酸酯共聚物(諸如Eudragit. RTM. RS及RL),聚丙烯酸及聚丙烯酸酯及甲基丙烯酸 醋共聚物(諸如Eudragit. RTM. S及L),聚乙烯縮醛二 乙基胺基乙酸酯,琥珀酸乙酸羥丙基甲基纖維素及蟲膠。 〔較佳水凝膠及凝膠形成材料包括羧基乙烯基聚合物, 海藻酸鈉,羧甲基纖維素鈉,羧甲基纖維素鈣,羧甲基澱 粕納’聚乙稀醇,經乙基纖維素,甲基纖維素,明膠,殿 粉及基於纖維素之交聯聚合物(其中交聯度較低以便促進 水吸收及聚合物基質膨脹)’經丙基織維素,經丙基曱基 纖維素,交聯澱粉,微晶纖維素,甲殼素,胺基丙烯基_甲 基丙烯酸酯共聚物(Eudragit.RTM. RS-PM ),支鏈澱粉, 膠原,酷·蛋白’瓊脂’阿拉伯膠’可溶脹親水性聚合物(諸 〆 如叛曱基纖維素鈉)’聚(甲基丙烯酸羥基烷酯)(分子量 為約5 k_5,000 k),聚乙烯基吡咯啶酮(分子量為約10 k-360 k) ’陰離子及陽離子水凝膠,具有低乙酸酯殘餘之聚 乙稀醇’瓊脂與羧甲基纖維素之可溶脹混合物,順丁烯二 酸肝與苯乙烯、乙烯、丙烯或異丁烯果膠之共聚物(分子 量為約30 k-300 k),多醣(諸如瓊脂、阿拉伯膠、刺梧 桐膠、黃箸膠、海藻酸及瓜耳膠),聚丙烯醯胺,p〇ly〇xRTM. 聚氧化乙烯(分子量為約100 k-5,000 k) ,AquaKeep.RTM. 200908892 之二酯,交聯聚乙烯醇及聚N-乙 及澱粉羥基乙酸鈉(例如 丙烯酸酯聚合物,葡聚糖 細基-2 - π比π各。定_ , Explotab.RTM.)。 較佳親水性聚合妨1 ^ >办 σ物包括多醣,甲基纖維素,羧甲基纖 ,.隹素鈉或缓曱基纖維素舞,經丙基甲基纖維素,經丙基織 $素’經乙基纖維素’石肖基纖維素,叛甲基纖維素,纖維 素醚,聚氧化乙烯(例如 Polyox.RTM.,Union Carbide ), 甲基乙基纖維素’乙基羥基乙基纖維素,乙酸纖維素,丁 ( 酸纖維素,丙酸纖維素,明膠,膠原蛋白,澱粉,麥芽糊 精,支鏈澱粉,聚乙烯基吡咯啶酮,聚乙烯醇,聚乙酸乙 烯酯,甘油脂肪酸酯,聚丙烯醯胺,聚丙烯酸,甲基丙烯 酸或甲基丙稀酸之共聚物(例如Eudragit.RTM.),其他丙 烯酸衍生物’脫水山梨糖醇酯’天然膠,卵磷脂,果膠, 海藻酸鹽’海藻酸銨’海藻酸鈉,海藻酸鈣,海藻酸钟, 海藻酸丙二醇酯,瓊脂,及膠,諸如阿拉伯膠、刺梧桐膠、 刺槐豆膠、黃蓍膠、鹿角菜膠、瓜耳膠、三仙膠、硬葡聚 糖及其混合物及摻合物。 可將諸如增塑劑、潤滑劑、溶劑及其類似物之賦形劑 添加至包衣中。合適增塑劑包括(例如)羥基化大豆印磷 脂、乙醢化單甘油醋、輕基乙酸丁基鄰苯二甲醯基丁酯、 酒石酸二丁酯、鄰苯二甲酸二乙酯、鄰苯二甲酸二甲酯、 經基乙酸乙基鄰苯二曱醯基乙酯、丙三醇、丙二醇、三乙 酸甘油酯、檸檬酸酯、三-二乙基_醇(tripropioin)、二 乙酸甘油酯、鄰笨一甲酸二丁酯、乙醯基單甘油酯、聚乙 11 200908892 醇、蓖麻油、檸檬酸三乙酯、多元醇、甘油、乙 ^ 回更S旨、 乙酸甘油醋、擰檬酸乙醯基三乙酯、鄰苯二甲酸_ + 酯、鄰苯二曱 酸二異壬酯、鄰苯二曱酸丁基辛酯、壬二酸二辛酯 _ 〜〜求甲 己酯、鄰苯二曱酸丁基辛酯、鄰笨_甲 、環氧 曱 十一 酯、 酸二-2- 化樹脂酸酯(epoxidized tallate )、苯三曱酸三異辛t 鄰苯二甲酸二乙基己酯、鄰苯二甲酸二正辛酯、鄰笨_ 酸二異辛酯、鄰苯二甲酸二異癸酯、鄰苯二甲酸二正 烷醋、鄰苯二甲酸二正十三烷醋、苯三甲酸三乙=己十 己二酸二-2-乙基己酯、癸二酸二·2•乙基己酯、壬 乙基己酯、癸二酸二丁醋。 包衣層可為任何合適之改良釋放基質材料或合適 良釋放基質材料組合。該等材料為熟習此項技術者已^改 適合於實踐本發明之改良釋放基質材料包括(但不限 微晶纖維素、羧甲基纖維素鈉、羥基烷基纖維素(^如、 丙基甲基纖維素及Μ丙基纖維素)、聚氧化乙歸、燒^ 維素(例如甲基纖維素及乙基纖維素)、$乙:醇二= 烯基㈣錢、乙酸纖維素、丁酸乙酸纖維素、鄰笨二二 酸己酸纖維素、苯三甲酸乙酸纖維素、聚鄰苯二甲酸: 乙烯醋、聚甲基丙烯酸心旨、聚乙酸乙烯醋及其混合物。 如熟習此項技術者所已知,劑型之溶解特徵不僅可智 由最終劑型中之賦形劑之量及最終劑型之尺寸來控制,且 可藉由正確選擇及摻合各種分子量之給定聚合物來控制。 薄膜包衣錠劑可藉由使用諸如旋轉盤包衣法或空氣懸 洋法之技術對錠劑進行包衣以在錠劑上沈積鄰接薄膜層來 12 200908892 裝備通吊進彳7該程序以改良錠劑之美學外觀,但亦可進 订D亥程序以改良鍵劑之吞咽性,以遮蓋不良氣味或味道, 或改良難看的未包衣錠劑之常規特性。壓製鍵劑(例如但 不限於)可藉由將組份與意欲增添結合或崩解性質之賦形 仏昆口來製備。使用工業中熟知之方法及機械將混合物直 接壓製,或造粒後再壓製。 本文所述之營養補充系統之一或多種劑量單元亦可用 於傳遞益菌助生質。例示性益菌助生質包括寡醣,諸如葡 萄^果糖、木糖、半乳糖、乳糖、甘露糖、π拉伯糖、 D-岩藻糖、L_岩藻糖、鼠李糖、細出咖、驗㈣、巴拉 金糖(Palatinose)、IM〇、纖維二糖、龍膽二糖、果聚糖、 麥芽糊精、麥芽糖、蜜二糖、棉子糖、乳糖、panorich、 松三糖、raftiHne、raftil〇se、水蘇糖、蔗糖、塔格糖 (tagat〇Se)、木聚糖、果寡醣(F〇S)、半乳寡醣(G0S)、 大豆寡醣、乳果糖、麥芽募醣、木募醣、菊糖及分級菊糖 (fractionated inulin )以及一或多種膳食纖維組份,諸如 椰子(包括椰子胚乳纖維)、甜菜漿(諸如甜菜渣)、菊 苣(包括菊苣漿)、燕麥糠濃縮物、米糠、刺槐豆、塔爾 哈型阿拉伯膠(gum talhar )及瓜爾膠。 將參考以下詳述製備劑量單元之某些程序之特定討論 及實施例更好理解營養補充系統。所有提及特定實施例均 係出於說明之目的。其不應認為限制本發明之範疇及本 質。 第二劑量單元經調配以含有一或多種通常極迅速吸收 13 200908892 且因此最佳藉由持續釋放傳遞以保持體内隨時間升高之濃 度的水溶性營養及/或其他營養。 某些迅速吸收之通常為水溶性之營養最佳藉由持續釋 放傳遞以保持體内隨時間升高之濃度。其包括B維生素及 維生素C °若以即刻釋放劑量單元形式給予,則體内該等 維生素之農度在初始峰值之後迅速降低。此外,腸壁中之 吸收位點及營養吸收機構會無法承受由快速釋放劑量單元 所造成之腸内高營養濃度,已知此舉會減少可由身體吸收 之總量。該等維生素之持續釋放劑量單元已用於克服該等 問題。但該等維生素之持續釋放劑量單元通常排除維生素 B 12 ’因為已認識到需要將全部劑量之維生素B 12傳遞至 胃中以使其可與内在因子組合。 測試現展示,與在胃中即刻釋放相比,由持續釋放所 傳遞之維生素B12可造成改良的維生素B12之生物可用 性。在所進行之特定測試中,向個體給予含有9·8 維生 素B1、11.5 mg維生素b2、^ mg維生素b6、9〇叫維 生素B12及518mg維生素C之錠劑。對於b維生素而言, 攝取相當即刻釋放調配物B1、62及B6在攝取後2小時產 生峰值血漿濃度而血清維生素B12在攝取後3小時產生峰 值。隨後B維生素濃度迅速自峰值濃度降低,B1及B6經 6 hr回復至基線而B2及Bu經12心回復至基線。相比之 下’攝取持續釋放調配物延遲B1及B2 (直至4 hr)以及 B6及B12 (直至5 hr)之峰值血清及血漿濃度。發現持續 釋放錠劑傳遞與即刻釋放傳遞相比,改良維生素c及至少 200908892 三種B維生素(包括維生素B12)之生物可用性。 因此第三劑量單元經調配以在上GI道之胃及腸中有 利地以大於維生素B12之DV (每日值)之量或以多個DV 含量之量釋放維生素B12。此藉由包括從 3 meg 至 500 meg 之置的維生素B12完成,其中從6 meg至500 meg之維生 素B12量達成最佳結果。 傳遞維生素B 12之最佳結果係以經6小時持續且大體 線性釋放維生素B12(由USP溶解裝置在37。(:下,以50RPM 之授拌槳速度,在900 ml 0. IN HC1中測定)之劑量單元 達成。劑量單元經調配以使得至少丨5 %之維生素B12在3 7 °C下在一小時内溶解於900 ml 0.1 N HC1中尤其有利。該 劑型在被個體攝取之後將維持維生素B 12之血漿含量歷時 12小時。維生素B12之良好傳遞(例如)以具有350 mg 至1500 mg總重量之第三劑量單元錠劑達成,其中該錢劑 含有20 meg至100 mCg維生素B12且含有5重量%至20 重量〇/。1^]\40:1^100/丑15。優良結果係以具有9.5%至14〇/〇 HPMC K100/E15之錠劑達成。 第三劑量單元亦可用於傳遞一或多種其他水溶性營 養’尤其其他B維生素及維生素c,有利地以其DV (每 曰值)或高於其DV或多個DV含量,若適當時。因此劑 量單元將有利地包括30 mg至750 mg維生素C、1 mg至40 mg維生素Bl ' 1 mg至40 mg維生素B2、10 mg至300 mg 煙酸、10 mg至300 mg維生素B5及i mg至40 mg維生素 B6。尤其有用之調配物包括從3〇 mg至750 mg維生素c、 15 200908892 從25 mg至400 mg鈣、從1 mg至40 mg維生素Bl、從i mg 至40mg維生素B2、從i0mg至3〇〇mg維生素b5、從1 mg 至40 mg維生素B6、從6 meg至500 meg維生素bi2、從 1 mg至100 mg生物類黃酮複合物及從5 mg至3〇〇 mg槲 皮酮。 第三劑量單元經設計以便以大體線性之方式緩慢釋放 一或多種該等水溶性營養。水溶性營養之釋放通常應在胃 及小腸(十二指腸、空腸及迴腸)中發生。 f 一般而言,當如通常所推薦隨餐服用補充劑時,需要 約6-1 2小時通過胃及小腸。因此水溶性維生素自第三劑量 單元釋放應在攝取之後延續至少三小時,且有利地在攝取 之後延續長達整整12小時。第三劑量單元亦有利地經調 配以釋放維生素B12以使維生素B12之血漿含量維持至少 6小時,其中當經調配以使維生素B12之血漿含量在攝取 之後維持30分鐘至24小時時達成最佳結果。 呈持續釋放錠劑形式之第三營養補充劑量單元之例示 ( 性調配物如下表所示: 持_釋放維生素B+C錠劑 成份 標示量(Label Claim )(每劑) 抗壞血酸鈣(Ca) 43 mg 抗壞血酸鈣(維生素c) 38U mg 碳酸妈(Ca) 7 mg 單硝酸硫胺 $驗醯胺 7.5 mg 8.5 mg Tool^ 泛酸妈 50 mg 盟酉曼U比σ多醇 10 mg 16 200908892 維生素b12 30 meg 柑#生物類黃酮 25 mg 槲皮酮 50 mg 微晶纖維素 n/a 硬脂酸鎂 n/a 二氧化矽 n/a 羥丙基甲基纖維素 n/a 經基化大豆印攝脂 n/a 將錠劑内容物混合且自所得混合物形成錠劑。將包衣 成份混合且將所得混合物用於對錠劑進行包衣。 鑒於本發明所揭示之原理可應用之許多可能的具體實 例,應認識到所說明之具體實例僅為本發明之較佳實施例 且不應認為其限制本發明之範疇。實際上,本發明之範疇 係由以下申請專利範圍界定。 【圖式簡單說明】 無 【主要元件符號說明】 益 17
Claims (1)
- 200908892 十、申請專利範圍·· 1. 一種由人類個體使用之口服營養補充劑量單元,其 中 、 該劑量單元包含維生素B12 ;且 該劑量單元為提供該維生素B12之持續釋放的持續釋 放劑量單元,該持續釋放係於人類個體之胃中開始且於小 腸中繼續一段時間。 2·如申請專利範圍第丨項之劑量單元,其經調配以提 " 供在攝取之後歷時至少12小時的高維生素B12血漿含量。 θ 3.如申請專利範圍第1項之劑量單元,其經調配以使 侍至少15%之該維生素Β12在37t下在一小時内溶解於 900 ml 〇 IN HC1 中。 4.如申請專利範圍第丨項之劑量單元,其另外包含: —或多種其他B維生素;及 維生素C。 5 ·如申請專利範圍第1項之劑量單元,其包含: 從30 mg至750 mg之維生素c、 從25 mg至400 mg之約、 從1 mg至40 mg之維生素b 1、 從1 mg至40 mg之維生素B2、 從1 0 mg至3 00 mg之維生素B5、 從1 mg至40 mg之維生素B6、 從6 meg至5 00 meg之維生素B 12、 從1 mg至100 mg之生物類黃酮複合物,及 18 200908892 從5 mg至300 mg之槲皮酮。 6. 如申請專利範圍第5項之劑量單元,其經調配以使 得至少15%之該等B維生素及維生素c在37Ό下在一小 時内溶解於900 ml 0· IN HC1中。 7. 如申請專利範圍第1項之劑量單元,其係呈錠劑 (tablet)或囊片(caplet)之形式。 8. 如申請專利範圍第7項之劑量單元,其另外包含外 部薄膜包衣。 9. 一種由人類個體使用之口服營養補充劑量單元其 中: 該劑量單元為包含以下各物之錠劑或囊片: 從30mg至750mg之維生素c, 從25 mg至400 mg之約, 從1 mg至40 mg之維生素b 1, 從1 mg至40 mg之維生素B2, 從10 mg至300 mg之維生素B5, 從1 mg至40 mg之維生素B6, 從6 meg至500 meg之維生素B12, 從1 mg至100 mg之生物類黃酮複合物,及 從5 mg至3 00 mg之樹皮酮;且 该劑量單元為提供該維生素B 1 2之持續釋放的持續釋 放劑量單元,該持續釋放係於人類個體之胃中開始且於小 腸中繼續一段足以提供在攝取之後歷時至少丨2小時的高 維生素B 12血漿含量的時間。 19 200908892 ιο_—種向人類個體傳遞維生素B12之方法,該方法勺 含向人類個體經口投予持續釋放之營養補充劑量單, 中: 〃 該劑量單元包含維生素B12;且 該劑量單元經調配以於胃中開始且於上腸道中繼續 放該維生素B 12。 ' 11_如申請專利範圍第10項之方法,其中該劑量單元 經調配以提供在攝取之後歷時至少12小時的高維生素B = 血漿含量。 12. 如申請專利範圍第1〇項之方法,其中該劑量單元 經調配以使得至少15%之該維生素B12在37t下在—小時 内溶解於900 ml 0.1N HC1中。 13. 如申請專利範圍第10項之方法,其中該劑量單元 另外包含: 一或多種其他B維生素;及 維生素C。 14. 如申請專利範圍第13項之方法,其中該劑量單元 經調配以使得至少15%之該等維生素B及維生素C在37 C下在小日守内溶解於900 ml 0.IN HC1中。 15. 如申研專利範圍第14項之方法,其中該劑量單元 係呈錠劑或囊片之形式。 16·如申請專利範圍第15項之方法,其中該劑量單元 具有外部薄膜包衣。 17'種向人類個體傳遞維生素B12之方法,該方法包 20 200908892 ^向人類個體經口投予持續釋放之營養補充劑量單元,其 该劑量單元為包含以下各物之錠劑或囊片. 從3〇111§至75〇mg之維生素c, 從25 mg至400 mg之約, 從1 mg至40 mg之維生素b 1, 從1 mg至40 mg之維生素B2, 從1〇 mg至3 00 mg之維生素B5, 從1 mg至40 mg之維生素B6 從6 meg至500 meg之維生素B12, 從1 mg至100 mg之生物類黃酮複合物,及 從5 mg至3 00 mg之槲皮酮;且 該劑量單元經調配以☆胃中開始且於上腸冑中繼續釋 放j維生素B12,而足以提供在攝取之後歷時至少12小時 的高維生素B12血漿含量。 十一、圖式: 無 21
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95394407P | 2007-08-03 | 2007-08-03 | |
US95393407P | 2007-08-03 | 2007-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200908892A true TW200908892A (en) | 2009-03-01 |
Family
ID=40341943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097129487A TW200908892A (en) | 2007-08-03 | 2008-08-04 | Nutritional dosage unit |
Country Status (7)
Country | Link |
---|---|
US (2) | US20100143533A1 (zh) |
JP (1) | JP2010535767A (zh) |
CN (1) | CN101815509A (zh) |
CA (1) | CA2695366C (zh) |
MX (1) | MX2010001260A (zh) |
TW (1) | TW200908892A (zh) |
WO (2) | WO2009020595A2 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096564A2 (en) * | 2009-02-19 | 2010-08-26 | Probiohealth Llc | Dietary supplements containing polyunsaturated omega-3 fatty acids and probiotic bacteria with potential gastrointestinal and dermatological benefits |
US8853269B2 (en) * | 2010-02-04 | 2014-10-07 | Copperhead Chemical Company Inc. | Composition and method for treating infections and promoting intestinal health |
WO2011099031A1 (en) * | 2010-02-11 | 2011-08-18 | Zota Health Care Limited | Active antioxidants for all age group |
JP2012183063A (ja) * | 2011-02-14 | 2012-09-27 | Suntory Holdings Ltd | ケルセチン配糖体配合容器詰め飲料 |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
WO2015157428A1 (en) * | 2014-04-08 | 2015-10-15 | Mayo Foundation For Medical Education And Research | Ingestible capsule |
EP2962578A1 (en) * | 2014-06-30 | 2016-01-06 | Richard Hubertus Verheesen | Method of providing a plurality of nutrition portions to a user and packaging product |
KR20170021350A (ko) * | 2014-07-01 | 2017-02-27 | 프로비 유에스에이, 인코포레이티드 | 이층 이중 방출 프로바이오틱 정제 |
US20160073666A1 (en) * | 2014-09-16 | 2016-03-17 | New Chapter, Inc. | Supplement for a Breastfeeding Woman |
EP3242565A4 (en) * | 2015-01-07 | 2018-06-27 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
WO2017048859A1 (en) * | 2015-09-16 | 2017-03-23 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
AU2016353091B2 (en) * | 2015-11-10 | 2022-07-14 | Probiotech Llc | Probiotic delivery systems |
US11291683B2 (en) | 2016-04-01 | 2022-04-05 | Access Business Group International Llc | Bilayer tablets of B vitamins and process for preparing the same |
MX2019006464A (es) * | 2016-12-09 | 2019-08-21 | Balchem Corp | Nutrientes esenciales y metodos relacionados. |
CN108836948B (zh) * | 2018-06-11 | 2024-04-12 | 宁波西敦医药包衣科技有限公司 | 一种利用包衣技术实现营养素可控制释放的产品 |
US20190388344A1 (en) | 2018-06-22 | 2019-12-26 | Probiotech Llc | Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
EP0208362A1 (en) * | 1985-06-28 | 1987-01-14 | The Procter & Gamble Company | Dietary supplements containing iron and enterically coated calcium |
NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
US5445826A (en) * | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
CH680263A5 (zh) | 1989-07-20 | 1992-07-31 | Norman Godin | |
WO1991011117A2 (en) * | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
WO1994006415A1 (en) * | 1992-09-23 | 1994-03-31 | Kv Pharmaceutical Corporation | Multi-vitamin and mineral supplement for pregnant women |
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
CA2199005A1 (en) * | 1994-09-01 | 1996-03-07 | Emile Bourland (Deceased) | Compositions and methods for delivery of polypeptides |
AU5252299A (en) * | 1998-08-04 | 2000-02-28 | Kv Pharmaceutical Company | Multi-vitamin and mineral supplements for women |
US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
US6805880B1 (en) * | 1999-08-20 | 2004-10-19 | Ferrosan A/S | Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress |
GB0007419D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
WO2002085415A1 (en) * | 2001-04-17 | 2002-10-31 | Biomatrix, Inc | Non-digestible sugar-coated products and process |
US6814983B2 (en) * | 2002-12-10 | 2004-11-09 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
ITMI20042189A1 (it) * | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
US20060270625A1 (en) * | 2005-05-13 | 2006-11-30 | Eastern Virginia Medical School | Nutraceuticals for the treatment of neuropathy |
-
2008
- 2008-08-04 WO PCT/US2008/009399 patent/WO2009020595A2/en active Application Filing
- 2008-08-04 WO PCT/US2008/009402 patent/WO2009035496A1/en active Application Filing
- 2008-08-04 MX MX2010001260A patent/MX2010001260A/es unknown
- 2008-08-04 JP JP2010519969A patent/JP2010535767A/ja active Pending
- 2008-08-04 CN CN200880101810A patent/CN101815509A/zh active Pending
- 2008-08-04 CA CA2695366A patent/CA2695366C/en active Active
- 2008-08-04 TW TW097129487A patent/TW200908892A/zh unknown
-
2010
- 2010-02-03 US US12/699,798 patent/US20100143533A1/en not_active Abandoned
-
2014
- 2014-02-28 US US14/194,528 patent/US9248095B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010535767A (ja) | 2010-11-25 |
US20100143533A1 (en) | 2010-06-10 |
MX2010001260A (es) | 2010-04-07 |
CA2695366A1 (en) | 2009-02-12 |
CA2695366C (en) | 2016-10-04 |
WO2009020595A3 (en) | 2009-04-09 |
US20140178347A1 (en) | 2014-06-26 |
WO2009035496A1 (en) | 2009-03-19 |
WO2009020595A2 (en) | 2009-02-12 |
US9248095B2 (en) | 2016-02-02 |
CN101815509A (zh) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200908892A (en) | Nutritional dosage unit | |
US9763989B2 (en) | Nutritional supplement system | |
US20050214388A1 (en) | Multivitamin formulations containing controlled-release magnesium | |
GB2212396A (en) | Dietary supplement comprising calcium and delayed release coated iron | |
EP3435788B1 (en) | Bilayer tablets of vitamin | |
JP2009525992A (ja) | コーティングを施した錠剤、その製造方法、及び関連する使用 | |
JP2023016043A (ja) | ガンマ-ポリグルタミン酸および亜鉛組成物 | |
NO320546B1 (no) | Prebiotiske kombinasjonsprodukter | |
CN109152772A (zh) | 烟酰胺的口服药物组合物 | |
WO2010096067A1 (en) | Controlled release budesonide minitablets | |
WO2010096068A1 (en) | Controlled release budesonide minitablets | |
JP2023546794A (ja) | 抗生物質に曝露した後で腸内マイクロバイオームのバランス回復のためのビタミンの直接的送達 | |
CN110368369B (zh) | 钙补充剂及其制备方法 | |
CN114585380A (zh) | 胃肠健康组合物 | |
TWI834984B (zh) | 控制釋放口服製劑及其製備方法 | |
WO2023004733A1 (zh) | 控制释放口服制剂及其制备方法 | |
TW202412743A (zh) | 用於控制釋放活性劑的含改質樹薯澱粉的多層配方 | |
WO2023205222A1 (en) | Multilayer formulation comprising modified tapioca starch for controlled-release of active agents | |
TW202304454A (zh) | 控制釋放口服製劑及其製備方法 | |
CN116490175A (zh) | 维生素直接递送以在暴露于抗生素后平衡肠道微生物 | |
TW202038914A (zh) | 用於改良型釋放藥物配方的可包覆核心 | |
CA3116039A1 (en) | Human dietary supplement and method for treating digestive system and immune-related disorders | |
CN101869711A (zh) | 含有利尿剂类降血压药物和双胍类降糖药物的药物组合物及其用途 | |
WO2018142359A1 (en) | Composition comprising immediate release and extended release capecitabine | |
CN105232554A (zh) | 一种治疗或预防肥胖型高血脂的药物组合物 |